Fortress Biotech Inc
FBIO3.540USD
+0.220+6.63%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
109.76MMarket Cap
LossP/E TTM
More Details of Fortress Biotech Inc Company
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Fortress Biotech Inc Info
Ticker SymbolFBIO
Company nameFortress Biotech Inc
IPO dateNov 17, 2011
CEORosenwald (Lindsay A)
Number of employees101
Security typeOrdinary Share
Fiscal year-endNov 17
Address1111 Kane Concourse
CityBAY HARBOR ISLANDS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33154
Phone17816524500
Websitehttps://www.fortressbiotech.com/
Ticker SymbolFBIO
IPO dateNov 17, 2011
CEORosenwald (Lindsay A)
Company Executives of Fortress Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-27.60%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
27.44K
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
13.60K
+24.89%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-27.60%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
27.44K
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
13.60K
+24.89%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Apr 2
Currency: USDUpdated: Wed, Apr 2
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
FY2019
By BusinessUSD
Name
Revenue
Proportion
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosenwald (Lindsay A)
13.25%
Weiss (Michael S)
5.80%
The Vanguard Group, Inc.
3.06%
Summit Financial, LLC
1.43%
Susquehanna International Group, LLP
1.15%
Other
75.31%
Shareholders
Shareholders
Proportion
Rosenwald (Lindsay A)
13.25%
Weiss (Michael S)
5.80%
The Vanguard Group, Inc.
3.06%
Summit Financial, LLC
1.43%
Susquehanna International Group, LLP
1.15%
Other
75.31%
Shareholder Types
Shareholders
Proportion
Individual Investor
20.12%
Investment Advisor
10.59%
Investment Advisor/Hedge Fund
2.69%
Hedge Fund
1.26%
Research Firm
0.51%
Bank and Trust
0.09%
Pension Fund
0.06%
Other
64.69%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
92
4.96M
26.50%
--
2025Q3
107
4.96M
27.33%
--
2025Q2
114
4.96M
27.45%
+47.82K
2025Q1
116
4.91M
27.75%
-3.29M
2024Q4
121
4.82M
26.63%
+370.47K
2024Q3
123
4.48M
24.67%
+822.95K
2024Q2
130
3.66M
27.39%
+620.10K
2024Q1
155
3.04M
28.91%
-2.56M
2023Q4
162
4.72M
15.96%
+3.18M
2023Q3
164
1.59M
428.37%
-108.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosenwald (Lindsay A)
4.11M
13.82%
-1.57M
-27.60%
Apr 17, 2025
Weiss (Michael S)
1.80M
6.05%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
852.92K
2.87%
+100.37K
+13.34%
Jun 30, 2025
Summit Financial, LLC
1.02M
3.41%
+1.02M
--
Jun 30, 2025
PVG Asset Management Corporation
321.96K
1.08%
-150.26K
-31.82%
Jun 30, 2025
Shikiar Asset Management, Inc.
278.47K
0.94%
+42.50K
+18.01%
Jun 30, 2025
Geode Capital Management, L.L.C.
234.79K
0.79%
-2.74K
-1.16%
Jun 30, 2025
Northern Trust Investments, Inc.
93.22K
0.31%
+57.31K
+159.61%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Date
Type
Ratio
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Fortress Biotech Inc?
The top five shareholders of Fortress Biotech Inc are:
Rosenwald (Lindsay A) holds 4.11M shares, accounting for 13.82% of the total shares.
Weiss (Michael S) holds 1.80M shares, accounting for 6.05% of the total shares.
The Vanguard Group, Inc. holds 852.92K shares, accounting for 2.87% of the total shares.
Summit Financial, LLC holds 1.02M shares, accounting for 3.41% of the total shares.
PVG Asset Management Corporation holds 321.96K shares, accounting for 1.08% of the total shares.
Rosenwald (Lindsay A) holds 4.11M shares, accounting for 13.82% of the total shares.
Weiss (Michael S) holds 1.80M shares, accounting for 6.05% of the total shares.
The Vanguard Group, Inc. holds 852.92K shares, accounting for 2.87% of the total shares.
Summit Financial, LLC holds 1.02M shares, accounting for 3.41% of the total shares.
PVG Asset Management Corporation holds 321.96K shares, accounting for 1.08% of the total shares.
What are the top three shareholder types of Fortress Biotech Inc?
The top three shareholder types of Fortress Biotech Inc are:
Rosenwald (Lindsay A)
Weiss (Michael S)
The Vanguard Group, Inc.
Rosenwald (Lindsay A)
Weiss (Michael S)
The Vanguard Group, Inc.
How many institutions hold shares of Fortress Biotech Inc (FBIO)?
As of 2025Q4, 92 institutions hold shares of Fortress Biotech Inc, with a combined market value of approximately 4.96M, accounting for 26.50% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.83%.
What is the biggest source of revenue for Fortress Biotech Inc?
In FY2023, the Targadox® business generated the highest revenue for Fortress Biotech Inc, amounting to 3.20M and accounting for 3.79% of total revenue.
